FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritisCJ Edwards, CA Birbara, Maria Paris et al.|Annals of the Rheumatic Diseases|2017Cited by 4
SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trialArthur Kavanaugh, J. Wollenhaupt, Gladman Dd et al.|Annals of the Rheumatic Diseases|2017Cited by 0